Clinical Trials

• P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz in HIV-Infected and HIV/TB Co-Infected

  Study Location: India

  Eligibility: Ages Eligible for Study:   3 Months to 35 Months   (Child) Sexes Eligible for Study:   All Accepts Healthy...

  Enrollment:

  Read More

• A5290, A Randomized, Phase 2b Study of a Double-Dose Lopinavir/Ritonavir-Based Antiretroviral

  Study Location: India

  Eligibility: Ages Eligible for Study:   18 Years and older   (Adult, Senior) Sexes Eligible for Study:   All Accepts Healthy...

  Enrollment:

  Read More

• A5279, Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of

  Study Location: India

  Eligibility: Ages Eligible for Study:   13 Years and older   (Child, Adult, Senior) Sexes Eligible for Study:   All Accepts...

  Enrollment:

  Read More

• A5302:  BioBank for Surrogate Marker Research for TB (B-SMART)

  Study Location: India

  Eligibility:

  Enrollment:

  Read More

• NWCS 445: Novel Biomarkers to Shorten TB Treatment

  Study Location: India

  Eligibility: Partncipants enrolled in “Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: a randomized,...

  Enrollment:

  Read More

• NWCS 414, Evaluation of a Serum Biosignature for Identifying HIV-infected Individuals at Greatest

  Study Location: India

  Eligibility: N/A

  Enrollment:

  Read More

• P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety

  Study Location: India

  Eligibility: Ages Eligible for Study:   up to 18 Years   (Child, Adult) Sexes Eligible for Study:   All Accepts Healthy...

  Enrollment:

  Read More

• A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)

  Study Location: Baltimore

  Eligibility: HIV infected men and women between the ages of 40 and 75 Co-enrolled in REPRIEVE and the Mechanistic (CT) substudy Taking...

  Enrollment:

  Read More

• HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir . . .

  Study Location: Baltimore

  Eligibility: HPTN 083 will enroll approximately 4500 HIV-uninfected MSM and TGW at risk for acquiring HIV infection, ages 18 or older at...

  Enrollment:

  Read More

• P2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics, Tolerability, and Safety of

  Study Location:

  Eligibility: Ages Eligible for Study:   18 Years and older   (Adult, Senior) Sexes Eligible for Study:   Female Accepts...

  Enrollment:

  Read More
•  < 1 2 3 4 >  Last ›